New cardiac ryanodine receptor inhibitors for the treatment of heart failure

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/1008477

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

We have discovered that a protein that is recognized for its role in phase II detoxification can also modify the calcium signaling that underlies heart function. The small part of the protein that is active in heart tissue differs from the enzyme center that supports detoxification and can thus be used as a therapeutic agent in heart failure and in genetic cardiac conditions. The project is to develop the cardio-active part of the protein for maximum efficacy and for eventual clinical use.

Funded Activity Details

Start Date: 01-01-2011

End Date: 01-01-2014

Funding Scheme: Project Grants

Funding Amount: $612,885.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Pharmacology and Pharmaceutical Sciences not elsewhere classified

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

calcium channels | cardiac arrhythmia | cardiac failure | cardiac ischaemia | glutathione S-transferases | heart failure | ryanodine receptor (RyR) | therapeutic agents

Related Links